Boston Therapeutics Inc. BTHE Archives - Page 2 of 2

TuesdayOct 29, 2013 2:41 pm

Boston Therapeutics, Inc. (BTHE) Pioneering Treatment of Diabetes, Directed by Experienced Leader

According to the American Diabetes Association, 25.8 million children and adults in the United States have diabetes. Around 27% of that population remains undiagnosed (7 million people), and 79 million people are estimated to be classified as pre-diabetic. In 2007 alone, diabetes was either listed as an underlying cause or contributing factor to over 231,000 deaths, a stark indicator of the life-threatening risk of this condition. Other figures show the economic impact of diabetes. According to figures supplemented in March 2013, the total costs of diabetes in the United States in 2012 was $245 billion, of which $176 billion was…

FridayOct 25, 2013 1:59 pm

Boston Therapeutics, Inc. (BTHE) and America’s Sugar Monster

The formal description for Boston Therapeutics is of a pharmaceutical company focused on the development of novel compounds based on complex carbohydrate chemistry to address unmet medical needs in diabetes. But the company’s potential, as an investment and in terms of its possible effect on the tens of millions of people with Type 2 diabetes, is far more dramatic. CEO David Platt is blunt about it, saying in a recent interview with the New Hampshire Union Leader that “We believe that what we have in our hands is an absolute blockbuster.” The blockbuster in question is the company’s one-of-a-kind proprietary…

WednesdayOct 16, 2013 8:45 am

Boston Therapeutics, Inc. (BTHE) to Present at Livingston Securities Advanced and Nano Life Sciences Summit

Boston Therapeutics today announces it will be making a presentation on a corporate update at the Livingston Securities Advanced and Nano Life Sciences Summit. The presentation is to be given by the President of Boston Therapeutics, Kenneth A. Tassey, Jr., on October 17, 2013, in New York City. Mr. Tassey, Jr. will cover Boston Therapeutics’ product pipeline, including PAZ320. Other topics of discussion to be covered during the presentation include the company’s product to reduce post-meal glucose elevation as well as other corporate developments. The presentation will be available on Boston Therapeutics' website: http://ir.stockpr.com/bostonti/overview. Headquartered in Manchester, NH, Boston Therapeutics…

TuesdayOct 15, 2013 9:18 am

Boston Therapeutics, Inc. (BTHE) Begins Research Study on PAZ320 at University of Minnesota

Boston Therapeutics today announces it has initiated a research study with the University of Minnesota on PAZ320, a complex carbohydrate-based drug designed to reduce the elevation of post-meal blood glucose by blocking the action of carbohydrate-hydrolyzing enzymes. Entitled "NMR studies of PAZ320 with sugar hydrolyzing enzymes", the study will be conducted by Kevin H. Mayo, Ph.D., a professor in the Department of Biochemistry, Molecular Biology, and Biophysics at the University of Minnesota, Minneapolis. Dr. Mayo commented, "PAZ320 appears to be a promising compound in the treatment of diabetes and deserves closer evaluation by the scientific community. This Boston Therapeutics-supported investigation…

FridayOct 11, 2013 11:39 am

Article Highlights Major Investment Points for Boston Therapeutics, Inc. (BTHE)

A recent BiotechStockTrader.com article (http://dtg.fm/SyR6), highlighting the unique and positive position that Boston Therapeutics now holds with regard to the multi-billion dollar diabetes drug industry, laid out the reasons why investors are starting to jump on board the still small biotech company. The company’s lead drug candidate, PAZ320, is the first diabetes drug to be based upon an important new technology, carbohydrate hydrolyzing enzyme inhibiting (CHEI). Unlike traditional diabetes drugs, PAZ320 doesn’t require insulin injections, and doesn’t involve interaction with important internal organs, such as the pancreas, kidneys, or liver. Instead, it is a simple chewable that operates in the…

FridayOct 04, 2013 5:01 pm

Boston Therapeutics, Inc. (BTHE) is “One to Watch”

Boston Therapeutics is a pharmaceutical company focused on the development and commercialization of novel compounds based on complex carbohydrate chemistry to address unmet medical needs. An IP portfolio solidifies the company's position in the pharmaceutical industry. Boston Therapeutics' current product pipeline, PAZ320 and IPOXYNT, is comprised of therapies developed to treat patient populations with Type 2 diabetes. PAZ320 is a non-systemic, non-toxic, chewable drug candidate for prevention of diabetes and its complications. PAZ320 inhibits the enzymes that release glucose from complex carbohydrate in foods during digestion. Boston Therapeutics believes PAZ320 is a safe and effective drug compound for people with…

Site Search

Company Search

Tag: Boston Therapeutics Inc. BTHE

Boston Therapeutics, Inc. (BTHE) Pioneering Treatment of Diabetes, Directed by Experienced Leader

Boston Therapeutics, Inc. (BTHE) and America’s Sugar Monster

Boston Therapeutics, Inc. (BTHE) to Present at Livingston Securities Advanced and Nano Life Sciences Summit

Boston Therapeutics, Inc. (BTHE) Begins Research Study on PAZ320 at University of Minnesota

Article Highlights Major Investment Points for Boston Therapeutics, Inc. (BTHE)

Boston Therapeutics, Inc. (BTHE) is “One to Watch”

Market Basics

Newsletter Publishers

Public Companies